John Maraganore - 15 Oct 2026 Form 4 Insider Report for CITY THERAPEUTICS, INC. (CTY)

Reporting relationship: Director
Issuer ticker: CTY
Reported as of: 15 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Oct 2026, 17:36:35 UTC
Prior SEC filing: 06 Jul 2026
Next SEC filing: 22 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Mary Beth DeLena, as Attorney-in-Fact

Filing notes and source

Key filing fact

John Maraganore filed Form 4 for CITY THERAPEUTICS, INC. (CTY) on 19 Oct 2026.

Key facts

This page summarizes John Maraganore's Form 4 filing for CITY THERAPEUTICS, INC. (CTY).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 19 Oct 2026, 17:36.

Change

Previous filing in this sequence was filed on 06 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001180432 Primary reporting owner

MARAGANORE JOHN

Relationship: Director
Address: 399 BINNEY STREET, CAMBRIDGE
Signature: /s/ Mary Beth DeLena, as Attorney-in-Fact
Signature date: 19 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTY transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +610,759
Change %: +71%
Price
Shares after: 1,470,692
Date: 19 Oct 2026
Ownership: Direct
Footnotes: F1

CTY holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 318,507
Date: 15 Oct 2026
Ownership: By John M. Maraganore 2021 Irrevocable Trust

CTY holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 318,507
Date: 15 Oct 2026
Ownership: By Christine Maraganore 2021 Irrevocable Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +22,649
Change %
Price: $0.000000^*
Shares after: 22,649
Date: 15 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,649
Exercise price: $18.00
Footnotes: F2

CTY transaction Derivative

Series Seed convertible preferred stock

Conversion of derivative security

Transaction value
Shares: -500,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 19 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 549,150
Exercise price
Footnotes: F1

CTY transaction Derivative

Series A convertible preferred stock

Conversion of derivative security

Transaction value
Shares: -56,095
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 19 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 61,609
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each share of Series Seed convertible preferred stock and Series A convertible preferred stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-to-1.0983 basis at the option of the holder, and automatically converted into Common Stock upon the closing of the Issuer's initial public offering on October 19, 2026 without payment of consideration. The Preferred Stock had no expiration date.

Footnote F2

The shares underlying this option vest in full upon the earlier of (i) October 15, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.